

**ASX Announcement**

29 August 2025

## Retirement of Non-Executive Directors

BCAL Diagnostics Limited (ASX: BDX) ("BCAL") advises Mr Mark Burrows (AO) and Mr Ron Phillips (AO) have retired as Non-Executive Directors of the Company, effective 28 August 2025.

BCAL Executive Chair Jayne Shaw said, *"Mark and Ron have made significant contributions during their tenure, providing valuable guidance and stewardship during a period of growth and strategic development. Their leadership, insights and commitment have been instrumental in strengthening BCAL's governance, positioning the Company for success. We extend our sincere thanks to Mark and Ron for their dedicated service and wish them well in future endeavours."*

The Board has determined that only one of the retiring Non-Executive Director positions will be replaced and a search process is currently underway.

*This announcement has been approved for release by the Board of BCAL Diagnostics Limited.*

**ENDS**

For further information:

**Corporate**

Shane Ryan

[sryan@bcaldiagnostics.com](mailto:sryan@bcaldiagnostics.com)

+61 (0) 437 192 869

**Media**

Rama Razy

[rama.razy@automicgroup.com.au](mailto:rama.razy@automicgroup.com.au)

+61 (0) 498 440 142

**About BREASTEST *plus*™**

BREASTEST *plus*™ is the first product in BCAL's BREASTEST® range of non-invasive, lipid-based breast cancer diagnostics. BREASTEST *plus*™ is a 'rule-out' test that has been designed to be used in women with dense breasts and alongside mammography to improve screening and diagnostic outcomes for women.

**About BCAL**

BCAL is an Australian biotechnology company dedicated to advancing early and accurate breast cancer detection. Our innovative, non-invasive blood test, the first in the BREASTEST® range of products, is designed to complement existing breast screening methods and provide additional lipidomic insights to rule-out breast cancer, empowering women and providing their clinicians with greater confidence in diagnostic outcomes. Improved screening accuracy potentially reduces the need for further investigation and biopsy resulting in better health outcomes for women.

Founded in 2010, BCAL is headquartered in Sydney, AUS and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/> or contact [info@bcaldiagnostics.com](mailto:info@bcaldiagnostics.com).